A nutritional supplement composition, is disclosed. The nutritional supplement composition includes one or more vitamins and mixtures. The one or more vitamins and mixtures are selected from the group consisting of an iron supplement comprising a combination of active ingredients. The active ingredients include carbonyl iron. The active ingredients include vitamin C. The active ingredients include ginger.

Provided is a method for preventing or improving UV-induced skin damage of a subject in need thereof, which comprises administering to the subject an effective amount of a composition containing hydrangenol derived from the extract of Hydrangea serrata as an active ingredient. The composition containing hydrangenol derived from the extract of Hydrangea serrata is able to increase secretion of hyaluronic acid and procollagen type-1 and inhibit secretion of MMP-1 in skin cells, and therefore effective in preventing or improving UV-induced damage of skin cells. Accordingly, the hydrangenol-containing composition is usefully available as a quasi-drug, drug, food, or cosmetic composition.

The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, in particular for use in the treatment and/or prevention of dental caries and/or periodontal disease. In particular, the present invention relates to microorganisms or mixtures thereof for use as an anti-inflammatory agent in the oral cavity for reducing or inhibiting the release of certain inflammatory factors. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the microorganisms as probiotic agents as well as a method of production thereof.

A mixture for the chewing gum which includes a powder-mixture and of a core composed of normal substances for the manufacture of chewing gum (sorbitol, Arabic gum, aromatic substances) and from the addition of the two active substances of caffeine and taurine in a concentration of caffeine from 0.77% to 3.75% and of taurine from 7.7% to 39.6% by weight. The taste of this mixture is deprived of a significant bitterness by the addition of Galium odoratum (woodruff) in a concentration of from 0.3% to 7% by weight, alternatively, it may be replaced by or supplemented with green tea from 0.2% to 4% by weight, where these additives reduce the bitterness of the mixture. It is also possible to add the above substances directly into the core, where, however, the concentration of the content of those substances is lower.

Provided are: a composition having an excellent anti-norovirus effect; use of a theaflavin compound for the preparation of the composition; and a method for preventing infection with a norovirus using a theaflavin compound. A theaflavin compound is used as an active ingredient for preventing infection with a norovirus. The theaflavin compound is preferably used together with an alcohol. The theaflavin compound is preferably one or more members selected from the group consisting of theaflavin, theaflavin-3-O-gallate, theaflavin-3′-O-gallate and theaflavin-3,3′-O-digallate that are derived from tea components.

A chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the gum base includes one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum includes one or more cannabinoids, and wherein the release rate of the one or more cannabinoids is at least 10% by weight of the one or more cannabinoids within the first 5 minutes upon oral administration.

A method is provided of making a medicinal delivery system which satiates a craving in an individual when the medicinal delivery system is administered orally to the individual. A coating composition is applied on a saliva-soluble powder to establish a coated powder, the coating composition featuring an at least partially solubilized craving satiation medicinal compound. The coated powder is combined with an edible carrier base to establish a medicinal delivery system that rapidly releases medicine and buffer preferably followed by slower, sustained release.

The present invention relates to a chewable oral gum (OG) formulation comprising at least one pharmaceutically active ingredient. The formulation comprises gelatin, glycerol, sorbitol and water, present in a specific ratio. The present invention also relates to a process particularly well-suited toprepare said chewable oral gum formulation.

A composition for the treatment of follicular tonsillitis is provided. The composition includes a therapeutically effective amount of carnosic acid and a carrier consisting of pharmaceutically acceptable solvents and ingredients. The composition is in the form of spray and includes ethanol and polyoxyethylenesorbitan monooleate and at least 0.1% oregano essential oil. Other compositions and treatment methods are disclosed.